Search
Now showing items 4391-4397 of 4397
Genomic evolution shapes prostate cancer disease type.
(ELSEVIER, 2024-03-13)
The development of cancer is an evolutionary process involving the sequential acquisition of genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly proliferate and eventually invade ...
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
(ELSEVIER SCI LTD, 2024-05-26)
INTRODUCTION: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. ...
BRCA awareness and testing experience in the UK Jewish population: a qualitative study.
(BMJ PUBLISHING GROUP, 2024-06-20)
BACKGROUND: 1 in 40 UK Jewish individuals carry a pathogenic variant in BRCA1/BRCA2. Traditional testing criteria miss half of carriers, and so population genetic testing is being piloted for Jewish people in England. There ...
DNA-PKcs is required for cGAS/STING-dependent viral DNA sensing in human cells.
(CELL PRESS, 2024-01-19)
To mount an efficient interferon response to virus infection, intracellular pattern recognition receptors (PRRs) sense viral nucleic acids and activate anti-viral gene transcription. The mechanisms by which intracellular ...
Acceleration-Based Kalman Tracking for Super-Resolution Ultrasound Imaging In Vivo
(IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC, 2023-12-01)
Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology.
(NATURE PORTFOLIO, 2024-06-18)
Tumor genomic profiling is increasingly seen as a prerequisite to guide the treatment of patients with cancer. To explore the value of whole-genome sequencing (WGS) in broadening the scope of cancers potentially amenable ...
Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.
(TAYLOR & FRANCIS LTD, 2017-01-01)
Primary and secondary resistance to currently available licensed tyrosine kinase inhibitors poses a real clinical challenge in the management of advanced gastrointestinal stromal tumors. Within the frame of early phase ...